CDKN2A and cancer: However, when comparing duodenal adenocarcinomas to cancers of other small bowel sites, both CDKN2A (18% vs. 10%) and ERBB2 (13% vs. 4%) alteration rates were higher in duodenal adenocarcinomas [1].